Insurance vs Cash Pay for Telehealth Ketamine Treatment

Insurance covers ketamine therapy in only one form: Spravato (esketamine), the FDA-approved nasal spray for treatment-resistant depression. Cash-pay telehealth ketamine, which uses compounded ketamine prescribed off-label, is not covered by insurance and typically costs $129-$399 per month. The right choice between insurance vs cash pay for telehealth ketamine treatment depends on whether you meet Spravato's clinical criteria, how much convenience matters to you, and what you're willing to pay out of pocket. This guide breaks down what each option covers, what it costs, and how to decide.

Health insurance coverage for ketamine therapy is limited to one product: Spravato (esketamine nasal spray), which the FDA approved for treatment-resistant depression in 2019. The FDA (U.S. Food and Drug Administration) is the federal agency responsible for approving prescription medications and enforcing their labeled use. Because Spravato carries FDA approval, many commercial insurance plans, Medicare Part D, and some Medicaid programs cover it, typically after prior authorization and documentation that a patient has failed at least two adequate antidepressant trials.

Coverage generally includes the medication cost and some portion of the facility fee and monitoring required under the REMS (Risk Evaluation and Mitigation Strategy) program, an FDA safety framework requiring two hours of in-clinic observation after each dose. For a closer look at how Medicare specifically handles this coverage, see our guide to whether Medicare covers ketamine therapy.

Generic compounded ketamine prescribed off-label through telehealth programs is almost universally not covered by insurance. Insurers do not typically reimburse off-label compounded medications delivered through ketamine-specific telehealth platforms. Some patients can use insurance for the psychiatric evaluation portion of a telehealth ketamine program if the provider bills the consultation separately as a standard psychiatric visit, though this varies by provider and insurer.

Cash-pay telehealth ketamine programs follow a fairly consistent pricing structure. A typical monthly cost breaks down into three parts: the clinical consultation ($75-$150 per appointment), compounded ketamine medication plus pharmacy and shipping ($50-$150 per month), and platform or program fees ($50-$100 per month). Most all-inclusive monthly programs range from $129-$399 per month.

Over a six-month treatment course, total cash-pay costs typically run $774-$2,394. That is often less than the total cost of six Spravato sessions even with insurance, once copays, coinsurance, and deductible status are factored in. See our subscription vs. per-session pricing comparison and our generic ketamine vs. Spravato analysis for a fuller cost picture.

Cash-pay telehealth ketamine offers more flexibility than insurance-covered treatment. Patients can choose from multiple providers and treatment models without insurance network restrictions, and clinical judgment rather than an insurance formulary determines the protocol. Starting, adjusting, or stopping treatment does not require insurance authorization.

Insurance-covered Spravato carries more administrative overhead. Prior authorization can take days to weeks, treatment frequency and duration may be shaped by coverage limits, and switching doses or adjusting protocols may require additional authorization. Provider availability is also tied to interstate prescribing rules and state licensing, which can affect both cash-pay and insurance-covered options depending on where you live.

Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) give cash-pay patients a real tax advantage. An HSA is a tax-advantaged account available to people enrolled in a high-deductible health plan, and an FSA is a similar pre-tax account offered through many employers. Ketamine therapy prescribed by a licensed provider for a diagnosed medical condition typically qualifies as an eligible medical expense under both. According to IRS Publication 502, amounts paid for legally prescribed drugs and treatment for a diagnosed condition generally qualify as deductible medical expenses, the same standard HSA and FSA administrators use for reimbursement eligibility.

Paying with pre-tax HSA or FSA dollars effectively reduces the cost of telehealth ketamine by your marginal tax rate, often 20%-35%. A $300 per month program effectively costs $195-$240 per month when paid through an HSA or FSA.

Cash-pay patients can access the full range of telehealth ketamine providers operating in their state, which means more options for finding the right treatment model, clinical team, and price point. Patients seeking insurance-covered treatment are limited to providers enrolled in the Spravato REMS program who accept their specific plan. Depending on geography, that can mean fewer provider options and longer wait times. State-level rules also affect access; see our telehealth legality overview for how regulations vary by location.

The choice between insurance-covered and cash-pay ketamine therapy usually comes down to eligibility, convenience, and cost. If you have insurance that covers Spravato, can reach a certified facility, and meet the treatment-resistance criteria, insurance coverage can meaningfully reduce your financial burden. If you prefer at-home treatment, want more control over your provider and protocol, or do not meet Spravato's eligibility criteria, cash-pay telehealth ketamine may be the more practical route.

According to the National Institute of Mental Health, several treatment options exist for depression that does not respond to standard antidepressants, and ketamine-based therapies are among them. Many patients find that cash-pay telehealth ketamine, especially when paid through HSA or FSA funds, is a reasonable investment in treatment that would otherwise be inaccessible or logistically difficult. If you are still weighing whether ketamine is the right next step, our guide on treatment-resistant depression next steps covers how to evaluate readiness before choosing a payment path.